非奈利酮在心血管及相关疾病的研究进展  

Finerenone in treatment of cardiovascular and related diseases

作　　者：余万乾 沈文[1] 杨萍萍[2] 甘路金 姚雄达 邬涛[1] 吴清华[1] YU Wanqian;SHEN Wen;YANG Pingping;GAN Lujin;YAO Xiongda;WU Tao;WU Qinghua(Department of Cardiology,The Second Affiliated Hospital of Nanchang University,Nanchang,330000,China;Department of Endocrinology and Metabolism,The Second Affiliated Hospital of Nanchang University)

机构地区：[1]南昌大学第二附属医院心内科,南昌330000 [2]南昌大学第二附属医院内分泌代谢科

出　　处：《临床心血管病杂志》2022年第11期916-920,共5页Journal of Clinical Cardiology

基　　金：国家自然科学基金项目(No:81860068);国家自然科学基金孵育项目(No:2021YNFY12021)。

摘　　要：盐皮质激素受体拮抗剂在治疗心力衰竭方面起着至关重要的作用。目前认为,螺内酯、依普利酮等甾体类盐皮质激素受体拮抗剂可使心力衰竭和慢性肾脏疾病患者获益,但易导致高钾血症等不良反应,降低了临床使用率。非奈利酮是一种新型非甾体盐皮质激素受体拮抗剂,不仅在治疗心力衰竭和慢性肾脏疾病等方面具有更好的安全性和有效性,在心房颤动和心肌梗死等疾病的治疗中也发挥着重要作用。本文对非奈利酮在心血管及相关疾病治疗中的研究进展进行综述。Mineralocorticoid receptor antagonists(MRAs) play a vital role in the treatment of heart failure. Although MRAs such as spironolactone and eplerenone have been shown to benefit patients with heart failure and chronic kidney disease, their clinical use is limited due to more side effects such as hyperkalemia. Finerenone, as a new type of highly selective non-steroidal MRA, has better safety profile and tolerance in the treatment of heart failure and chronic kidney disease. In recent years, a number of studies and basic experiments have shown that finerenone has great potential in the treatment of hypertension and myocardial infarction. In this paper, we review the latest research progress of the efficacy and safety of finerenone in cardiovascular and other related diseases.

关 键 词：非奈利酮 非甾体类盐皮质激素受体拮抗剂 心血管疾病 

分 类 号：R541[医药卫生—心血管疾病]